AbCellera Biologics Inc.
ABCLHealthcareNASDAQBiotechnology · Last scanned May 28, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 27
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Valued at $1.66B, ABCL is a small-cap name in its sector. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
Market Cap
$1.66B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.56
EPS (TTM)
$-0.50
EPS (Fwd)
$-0.72
ROE
-14.7%
ROA
-10.0%
Cash
$504.7M
Total Debt
$134.3M
Free CF
-$105.4M
52W Change
166.7%
Annual Financials
Cash vs Debt
With $504.7M in cash and $134.3M in debt, ABCL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$105.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -14.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $485.4M (2022) to $75.1M (2025), a 85% decline worth watching.
With cash comfortably exceeding debt, ABCL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ABCL.